Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
| Data | Nome del titolare | Azioni transazionate | Intervallo di valore ($) | Tipo di transazione | Intervallo di prezzo ($) | Azioni a fine dichiarazione | % di variazione |
|---|---|---|---|---|---|---|---|
| 2026-04-02 | Mr. Ian F. SmithExecutive Chair | 3,44k | 0,00 | Derivative Exercise and Retained Stock | - | 134,71k | 2,62% |
| 2026-03-11 | RA Capital Management, L.P.Società | 3,16M | 23,71M | Acquisto | 7,28 - 7,79 | 8,83M | 55,61% |
| 2026-02-06 | RA Capital Management, L.P.Società | 354,94k | 2,30M | Acquisto | 6,49 | 5,67M | 6,67% |
| 2026-02-13 | Mr. Alexander G. CumboPresident, CEO & Director | 13,39k | 0,00 | Derivative Exercise and Retained Stock | - | 235,41k | 6,03% |
| 2026-02-13 | Mr. Alexander G. CumboPresident, CEO & Director | -16,64k | 96,92k | Derivative Exercise and Sale | 5,82 | 235,41k | - |
| 2026-02-13 | Dr. Jessie HanrahanChief Regulatory & Preclinical Operations Officer | 3,99k | 0,00 | Derivative Exercise and Retained Stock | - | 74,32k | 5,67% |
| 2026-02-13 | Dr. Jessie HanrahanChief Regulatory & Preclinical Operations Officer | -4,13k | 24,07k | Derivative Exercise and Sale | 5,82 | 74,32k | - |
| 2026-02-13 | Mr. Ilan GanotCo-founder, Strategic Advisor to the CEO & Director | 2,20k | 0,00 | Derivative Exercise and Retained Stock | - | 146,17k | 1,53% |
| 2026-02-13 | Mr. Ilan GanotCo-founder, Strategic Advisor to the CEO & Director | -2,66k | 15,48k | Derivative Exercise and Sale | 5,82 | 146,17k | - |
| 2026-02-13 | Mr. Paul HerzichCTO | 3,57k | 0,00 | Derivative Exercise and Retained Stock | - | 72,64k | 5,17% |
| 2026-02-13 | Mr. Paul HerzichCTO | -3,62k | 21,06k | Derivative Exercise and Sale | 5,82 | 72,64k | - |
| 2026-02-13 | Mr. David Tyronne HowtonCOO & Secretary | 7,22k | 0,00 | Derivative Exercise and Retained Stock | - | 105,08k | 7,38% |
| 2026-02-13 | Mr. David Tyronne HowtonCOO & Secretary | -7,47k | 43,49k | Derivative Exercise and Sale | 5,82 | 105,08k | - |
| 2026-02-13 | Dr. Gabriel BrooksChief Medical Officer | 5,37k | 0,00 | Derivative Exercise and Retained Stock | - | 89,47k | 6,39% |
| 2026-02-13 | Dr. Gabriel BrooksChief Medical Officer | -5,56k | 32,40k | Derivative Exercise and Sale | 5,82 | 89,47k | - |
| 2026-02-13 | Mr. Kevin TanCFO & Treasurer | 5,22k | 0,00 | Derivative Exercise and Retained Stock | - | 99,42k | 5,54% |
| 2026-02-13 | Mr. Kevin TanCFO & Treasurer | -5,40k | 31,47k | Derivative Exercise and Sale | 5,82 | 99,42k | - |
| 2026-02-04 | Mr. David Tyronne HowtonCOO & Secretary | -18,89k | 121,71k | Vendita | 6,44 | 97,86k | -16,18% |
| 2026-02-04 | Mr. Ilan GanotCo-founder, Strategic Advisor to the CEO & Director | -7,21k | 46,41k | Vendita | 6,44 | 143,96k | -4,77% |
| 2026-02-04 | Mr. Alexander G. CumboPresident, CEO & Director | -48,91k | 315,09k | Vendita | 6,44 | 222,02k | -18,05% |
| 2026-02-04 | Mr. Kevin TanCFO & Treasurer | -14,78k | 95,23k | Vendita | 6,44 | 94,20k | -13,56% |
| 2026-02-04 | Dr. Gabriel BrooksChief Medical Officer | -12,62k | 81,27k | Vendita | 6,44 | 84,09k | -13,05% |
| 2026-02-04 | Dr. Jessie HanrahanChief Regulatory & Preclinical Operations Officer | -12,35k | 79,54k | Vendita | 6,44 | 70,33k | -14,94% |
| 2026-02-04 | Mr. Paul HerzichCTO | -10,91k | 70,25k | Vendita | 6,44 | 69,07k | -13,64% |
| 2026-01-29 | Mr. Kevin TanCFO & Treasurer | 62,88k | 0,00 | Derivative Exercise and Retained Stock | - | 108,98k | 136,41% |
| 2026-01-31 | Mr. Kevin TanCFO & Treasurer | -26,84k | 172,75k | Derivative Exercise and Sale | 6,44 | 108,98k | - |
| 2026-01-29 | Mr. Alexander G. CumboPresident, CEO & Director | 189,54k | 0,00 | Derivative Exercise and Retained Stock | - | 270,93k | 232,89% |
| 2026-01-31 | Mr. Alexander G. CumboPresident, CEO & Director | -80,26k | 516,61k | Derivative Exercise and Sale | 6,44 | 270,93k | - |
| 2026-01-29 | Dr. Jessie HanrahanChief Regulatory & Preclinical Operations Officer | 56,02k | 0,00 | Derivative Exercise and Retained Stock | - | 82,68k | 210,11% |
| 2026-01-31 | Dr. Jessie HanrahanChief Regulatory & Preclinical Operations Officer | -26,54k | 170,80k | Derivative Exercise and Sale | 6,44 | 82,68k | - |
| 2026-01-29 | Dr. Gabriel BrooksChief Medical Officer | 58,74k | 0,00 | Derivative Exercise and Retained Stock | - | 96,71k | 154,69% |
| 2026-01-29 | Dr. Gabriel BrooksChief Medical Officer | -28,34k | 182,39k | Derivative Exercise and Sale | 6,44 | 96,71k | - |
| 2026-01-29 | Mr. David Tyronne HowtonCOO & Secretary | 83,85k | 0,00 | Derivative Exercise and Retained Stock | - | 116,75k | 254,79% |
| 2026-01-31 | Mr. David Tyronne HowtonCOO & Secretary | -37,77k | 243,13k | Derivative Exercise and Sale | 6,44 | 116,75k | - |
| 2026-01-29 | Mr. Paul HerzichCTO | 53,35k | 0,00 | Derivative Exercise and Retained Stock | - | 79,97k | 200,40% |
| 2026-01-29 | Mr. Paul HerzichCTO | -26,25k | 168,97k | Derivative Exercise and Sale | 6,44 | 79,97k | - |
| 2026-01-31 | Mr. Ilan GanotCo-founder, Strategic Advisor to the CEO & Director | 15,00k | 0,00 | Derivative Exercise and Retained Stock | - | 151,17k | 11,02% |
| 2026-01-27 | Mr. Ilan GanotCo-founder, Strategic Advisor to the CEO & Director | 4,08k | 0,00 | Derivative Exercise and Retained Stock | - | 136,17k | 3,09% |
| 2026-01-27 | Mr. Ilan GanotCo-founder, Strategic Advisor to the CEO & Director | -191,00 | 1,26k | Derivative Exercise and Sale | 6,59 | 136,17k | - |
| 2026-01-09 | Mr. Kevin TanCFO & Treasurer | 5,55k | 0,00 | Derivative Exercise and Retained Stock | - | 46,10k | 13,68% |
| 2026-01-09 | Mr. Kevin TanCFO & Treasurer | -5,70k | 30,06k | Derivative Exercise and Sale | 5,27 | 46,10k | - |
| 2026-01-06 | Mr. Ian F. SmithExecutive Chair | 4,57k | 0,00 | Derivative Exercise and Retained Stock | - | 131,26k | 3,61% |
| 2026-01-03 | Mr. Ilan GanotCo-founder, Strategic Advisor to the CEO & Director | 1,94k | 0,00 | Derivative Exercise and Retained Stock | - | 132,09k | 1,49% |
| 2026-01-03 | Mr. Ilan GanotCo-founder, Strategic Advisor to the CEO & Director | -1,05k | 5,72k | Derivative Exercise and Sale | 5,43 | 132,09k | - |
| 2025-12-02 | Mr. David Tyronne HowtonCOO & Secretary | 8,12k | 0,00 | Derivative Exercise and Retained Stock | - | 32,91k | 32,75% |
| 2025-12-02 | Mr. David Tyronne HowtonCOO & Secretary | -4,93k | 25,20k | Derivative Exercise and Sale | 5,11 | 32,91k | - |
| 2025-12-02 | Mr. Alexander G. CumboPresident, CEO & Director | 17,80k | 0,00 | Derivative Exercise and Retained Stock | - | 81,39k | 28,00% |
| 2025-12-02 | Mr. Alexander G. CumboPresident, CEO & Director | -10,81k | 55,23k | Derivative Exercise and Sale | 5,11 | 81,39k | - |
| 2025-12-02 | Dr. Jessie HanrahanChief Regulatory & Preclinical Operations Officer | 7,38k | 0,00 | Derivative Exercise and Retained Stock | - | 26,66k | 38,27% |
| 2025-12-02 | Dr. Jessie HanrahanChief Regulatory & Preclinical Operations Officer | -4,48k | 22,91k | Derivative Exercise and Sale | 5,11 | 26,66k | - |
| 2025-12-02 | Mr. Paul HerzichCTO | 4,54k | 0,00 | Derivative Exercise and Retained Stock | - | 26,62k | 20,55% |
| 2025-12-02 | Mr. Paul HerzichCTO | -2,70k | 13,80k | Derivative Exercise and Sale | 5,11 | 26,62k | - |
| 2025-11-10 | Mr. Ilan GanotCo-founder, Strategic Advisor to the CEO & Director | -3,28k | 13,51k | Vendita | 4,12 | 129,65k | -2,47% |
| 2025-10-18 | Dr. Gabriel BrooksChief Medical Officer | 6,86k | 0,00 | Derivative Exercise and Retained Stock | - | 33,82k | 25,42% |
| 2025-10-18 | Dr. Gabriel BrooksChief Medical Officer | -2,90k | 17,25k | Derivative Exercise and Sale | 5,96 | 33,82k | - |
| 2025-10-06 | Mr. Ian F. SmithExecutive Chair | 4,57k | 0,00 | Derivative Exercise and Retained Stock | - | 126,69k | 3,74% |
| 2025-06-16 | RA Capital Management, L.P.Società | 553,04k | 2,48M | Acquisto | 4,31 - 4,50 | 5,67M | 10,80% |
| 2025-07-06 | Mr. Ian F. SmithExecutive Chair | 4,57k | 0,00 | Derivative Exercise and Retained Stock | - | 122,12k | 3,89% |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Registrati con e-mail
Hai già un account? Accedi
Non hai un account? Registrati
Registrandomi, confermo di aver letto, capito, e accetto i termini e condizioni ADVFN e che sono un investitore privato.
Caratteristiche principali
Premium
